GSK's journey has been quite turbulent in the past few months. The pharmaceutical giant saw its drug Nucala receive approval in China for CRSwNP and resolved most of its US Zantac lawsuits, prompting a temporary rise in stocks. However, its RSV and shingles vaccines have underperformed, incurring a low for the company and causing shares to fall. The company also had an underwhelming performance with top two vaccine sales disappointing, and the stock declined 20% in 3 months. Despite the fluctuating pattern, GSK was suggested as a top value stock and an undervalued asset by some analysts. The company also initiated a block listing for 700,000 shares and seemed to be generating improved relative strength. GSK shares fell again after a recent Delaware court ruling regarding Zantac, and a warning of further vaccine sales drop in 2024 expected to hit earnings. Nevertheless, some opine that GSK's momentum might witness a rebound while bearish sentiment prevails due to weak pipeline visibility. All things considered, GSK stock remains under scrutiny whether it will rebound, sell, or hold in the coming days.
GSK Stocks News Analytics from Wed, 01 May 2024 07:00:00 GMT to Sat, 04 Jan 2025 12:47:30 GMT -
Rating -3
- Innovation -2
- Information 5
- Rumor -2
